Key Takeaways
- • Horizon Technology Finance (NASDAQ: HRZN) and Monroe Capital closed an initial $40 million senior credit facility for Ossio Inc. (OSSIO), with an additional $10 million available to support future growth, for a total of $50 million.
- • OSSIO, an orthopedics company founded in 2014, is developing OSSIOfiber Intelligent Bone Regeneration Technology as a metal-free replacement for metal implants in the global orthopedic fixation market.
- • The financing is positioned as growth capital to fund OSSIO's global expansion of its orthopedic fixation technology, according to CEO Brian Verrier.
- • Horizon's Chief Investment Officer Paul Seitz described the deal as another Horizon investment within the Israeli technology ecosystem, reflecting its focus on venture growth companies.
Summary
Horizon Technology Finance Corporation and Monroe Capital LLC have announced the closing of an initial $40 million senior credit facility for Ossio Inc., with an additional $10 million available to support future growth, according to a Business Wire release dated February 11, 2026. The facility brings the total available capital to $50 million.
OSSIO, founded in 2014, describes itself as an orthopedics company seeking to transform the surgical experience for patients, physicians, providers and payors. The company's stated goal is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market, using its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development and manufacturing in Caesarea, Israel, and runs commercial operations from Palmetto, Florida.
OSSIO CEO Brian Verrier said the company plans to execute its strategy to expand its orthopedic fixation technology globally, and that the financing provides resources to accelerate expansion while preserving the company's mission. Horizon's Chief Investment Officer Paul Seitz said the investment reflects Horizon's commitment to supporting innovative, venture growth companies through strategic financing and marks another Horizon investment in the Israeli technology ecosystem. Mark Solovy, Managing Director and Co-Head of Monroe Capital's Technology Finance Group, said Monroe sees exceptional innovation emerging from Israeli life sciences and that OSSIO's metal-free bone regeneration solutions align with the firm's technology finance vertical.
Horizon Technology Finance, externally managed by an affiliate of Monroe Capital, provides secured loans to venture capital and private equity-backed companies and publicly traded companies in technology, life science, healthcare information and services, and sustainability industries. Monroe Capital is a private credit asset manager active across direct lending, technology finance, venture debt and other strategies. The release did not disclose the loan's interest rate, maturity, or other terms.
OSSIO, founded in 2014, describes itself as an orthopedics company seeking to transform the surgical experience for patients, physicians, providers and payors. The company's stated goal is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market, using its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development and manufacturing in Caesarea, Israel, and runs commercial operations from Palmetto, Florida.
OSSIO CEO Brian Verrier said the company plans to execute its strategy to expand its orthopedic fixation technology globally, and that the financing provides resources to accelerate expansion while preserving the company's mission. Horizon's Chief Investment Officer Paul Seitz said the investment reflects Horizon's commitment to supporting innovative, venture growth companies through strategic financing and marks another Horizon investment in the Israeli technology ecosystem. Mark Solovy, Managing Director and Co-Head of Monroe Capital's Technology Finance Group, said Monroe sees exceptional innovation emerging from Israeli life sciences and that OSSIO's metal-free bone regeneration solutions align with the firm's technology finance vertical.
Horizon Technology Finance, externally managed by an affiliate of Monroe Capital, provides secured loans to venture capital and private equity-backed companies and publicly traded companies in technology, life science, healthcare information and services, and sustainability industries. Monroe Capital is a private credit asset manager active across direct lending, technology finance, venture debt and other strategies. The release did not disclose the loan's interest rate, maturity, or other terms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.